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Neurotransmitter deficits from frontotemporal
lobar degeneration
Alexander G. Murley1 and James B. Rowe1,2,3
Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia,
progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotrans-
mitter systems. We review the evidence for these neurochemical changes and propose that they contribute to symptomatology of
frontotemporal lobar degeneration, over and above neuronal loss and atrophy. Despite the development of disease-modifying
therapies, aiming to slow neuropathological progression, it remains important to advance symptomatic treatments to reduce the
disease burden and improve patients’ and carers’ quality of life. We propose that targeting the selective deﬁciencies in neurotrans-
mitter systems, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and gamma-aminobutyric acid is an im-
portant strategy towards this goal. We summarize the current evidence-base for pharmacological treatments and suggest strategies
to improve the development of new, effective pharmacological treatments.
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Introduction
Frontotemporal lobar degeneration (FTLD) causes diverse
clinical syndromes, including frontotemporal dementia
(FTD), progressive supranuclear palsy (PSP) and corticoba-
sal syndrome (CBS) (MacKenzie et al., 2010; Riedl et al.,
2014). In recent years there has been marked progress in
deﬁning these syndromes in terms of their clinical diagnos-
tic criteria (Gorno-Tempini et al., 2011; Rascovsky et al.,
2011; Armstrong et al., 2013; Ho¨glinger et al., 2017),
genetic association (Seelaar et al., 2011; Baizabal-Carvallo
and Jankovic, 2016), pathology (MacKenzie et al., 2010),
and clinical and imaging biomarkers (Whitwell et al., 2005;
Hughes et al., 2013; Skillback et al., 2014; Rohrer et al.,
2015b; Ranasinghe et al., 2016). These advances have sup-
ported the development of candidate disease-modifying
therapeutics (Boxer and Boeve, 2007; Tsai and Boxer,
2014; Stamelou and Ho¨glinger, 2016). However, treat-
ments that slow or halt disease progression after symptoms
begin must be accompanied by more effective treatment of
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symptoms to reduce the overall burden of disease. One
strategy is to reverse neurotransmitter deﬁcits, similar to
dopaminergic therapy of Parkinson’s disease or cholinergic
therapy for Alzheimer’s disease. Novel symptomatic drug
treatment would improve patients’ and their families’ qual-
ity of life.
Recent changes in the clinical and pathological character-
ization of the major clinical syndromes caused by FTLD
give anatomical and pharmacological insights that call for
a reappraisal of the neurotransmitter literature. We adopt
the clinical labels as set out in current consensus diagnostic
criteria for the behavioural variant FTD (bvFTD)
(Rascovsky et al., 2011), semantic variant of primary pro-
gressive aphasia (svPPA) (Gorno-Tempini et al., 2011),
logopenic variant of PPA (lvPPA) (Gorno-Tempini et al.,
2011), non-ﬂuent agrammatic variant PPA (nfvPPA)
(Gorno-Tempini et al., 2011), CBS (Armstrong et al.,
2013) and PSP (Ho¨glinger et al., 2017). However, older
studies may have used different terms or overlooked the
evolution of phenotype that obscures the boundaries be-
tween groups as the disease progresses (Coyle-Gilchrist
et al., 2016). Where these changes are relevant to the in-
terpretation of neurotransmitter effects, we make variations
from the current standard classiﬁcation explicit, but other-
wise consider semantic dementia as semantic variant PPA
and progressive non-ﬂuent aphasia as non-ﬂuent agram-
matic variant PPA.
Here we review the pharmacological abnormalities asso-
ciated with FTLD in terms of regional changes in neuro-
transmitter synthesis, release, reuptake, catabolism, and
synaptic binding. We focus on the major neurotransmitter
systems, dopamine, noradrenaline, serotonin, acetylcholine,
glutamate and gamma aminobutyric acid (GABA) both in-
dividually (including their receptor subtypes) and the inter-
actions between them. Table 1 provides a summary of the
available evidence, with full information on references by
disease and by neurotransmitter in Supplementary Table 1.
Dopamine
Dopaminergic deﬁcits are widely associated with Parkinson’s
disease but are also a common feature of FTLD. The ma-
jority of dopaminergic neurons originate in the ventral mid-
brain and form nigrostriatal, mesolimbic and mesocortical
projections (Fig. 1A). Nigrostriatal neurons from the sub-
stantia nigra pars compacta terminate in the striatum, reg-
ulating cortico-striato-thalamo-cortical loops for motor,
oculomotor and cognitive control (Rowe and Rittman,
2016). The motor circuit regulates movement, both in facil-
itating (via the direct pathway) and inhibiting (via the indir-
ect pathway) actions. Loss of dopaminergic neurons in the
nigrostriatal pathway causes parkinsonism in Parkinson’s
disease, but also in FTLD. Additional mesolimbic and meso-
cortical dopaminergic neurons from the ventral tegmental
area regulate reward, learning and motivation-related behav-
iour (Wise, 2004). The mesolimbic tract projects principally
to the nucleus accumbens in the striatum and to the amyg-
dala and hippocampus, affecting motivation, hedonia and
reward (incentive salience). Changes to the mesolimbic
tract may also exacerbate compulsion and impulsivity. The
mesocortical tract (which projects to the prefrontal, cingulate
and perirhinal cortices) regulates motivation, emotion,
reward and desire, including learning of the value of goal-
directed actions. Dopamine binds to ﬁve types of G protein
coupled receptors; D1-class (D1 and D5) and D2-class (D2,
D3 and D4), which differ in their response to dopamine
agonists and antagonists (Beaulieu and Gainetdinov, 2011;
Southan et al., 2016). The different receptor subtypes have
distinct distribution densities across brain regions and are
associated with different, although overlapping, effects on
cognition and movement (Beaulieu and Gainetdinov,
2011), and may be differentially affected by FTLD.
Frontotemporal dementia
There is clinical and experimental evidence of a nigrostria-
tal deﬁcit in many cases of FTD, with loss of pre-synaptic
dopaminergic neurons, reduced dopamine levels, reduced
dopamine transporter binding, and abnormal dopamine re-
ceptor binding. Extrapyramidal symptoms of bradykinesia,
rigidity and gait dysfunction are seen in up to 70% of
patients at some stage during the disease course (Rinne
et al., 2002; Padovani et al., 2007; Kertesz et al., 2011;
Table 1 Summary of neurotransmitter deficits in FTLD
Neurotransmitter pathway FTD PSP CBS
Dopamine
Dopaminergic neurons ## ## ##
Dopamine receptors # ##a $
Noradrenaline
Noradrenergic neurons $ ## na
Noradrenergic receptors na na na
Serotonin
Serotonergic neurons ## # #
Serotonergic receptors ## " na
Acetylcholine
Cholinergic neurons $b ## ##
Cholinergic receptors $/# $/# na
Glutamate
Glutamatergic neurons ## ## na
Glutamatergic receptors ## $ na
GABA na
GABAergic neurons # ## na
GABA receptors na # na
A more detailed table, including references, is included as Supplementary Fig. 1.
## = moderate/severe deficit; #= mild deficit; "/$/# = conflicting or inconsistent
results; $= no significant change; "= mild increase; na = no available evidence.
aIn PSP D2 receptors are reduced in the striatum and basal ganglia but D1 receptors
appear to be preserved.
bCholinergic neurons are reduced in the nucleus basalis but are preserved in the
cerebral cortex in bvFTD. In nfvPPA there is greater evidence of a cholinergic deficit
with atrophy of basal forebrain cholinergic nuclei.
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Figure 1 Dopamine deficits in FTD. (A) Schematic illustration of dopaminergic pathways. (B) Ioflupane SPECT scan showing loss of pre-
synaptic dopaminergic neurons in the striatum of FTD compared with normal scan. (C) Loss of dopaminergic neurons in the putamen (measured
by 11C-CFT-PET) correlates with severity of extra-pyramidal motor symptoms (Unified Parkinson’s Disease Rating Scale motor score). From
Rinne et al. (2002). Reprinted with permission from Wolter Kluwer. (D) Dopamine levels are reduced in the caudate, putamen and globus pallidus.
Graph of data from Kanazawa et al. (1988). Reprinted with permission from Elsevier. (E) There is loss of D2 dopamine receptors in the frontal
lobes (as measured by 123I-IBZM-PET). Graph of data from Frisoni et al. (1994). Reprinted with permission from Elsevier. (F) CSF DOPAC levels
(3,4-dihydroxyphenylacetic acid, a dopamine metabolite) correlate with behavioural disturbance. From Engelborghs et al. (2008). Reprinted with
permission from Elsevier.
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Gil-Navarro et al., 2013). In vivo imaging reveals that
dopamine transporter levels (a marker of presynaptic
neuron integrity in the striatum) are reduced in the caudate
and putamen (Fig. 1B) (Rinne et al., 2002; Sedaghat et al.,
2007). The degree of this loss correlates with extra-pyram-
idal symptom severity (Fig. 1C) (Rinne et al., 2002;
Sedaghat et al., 2007).
In bvFTD there are low levels of dopamine, measured by
high performance liquid chromatography, in the putamen,
caudate and substantia nigra (Kanazawa et al., 1988;
Nagaoka et al., 1995) (Fig. 1D). Parkinsonism is commonly
seen in bvFTD, especially when caused by certain genetic
mutations (Baizabal-Carvallo and Jankovic, 2016).
Mutations on chromosome 17, including in the MAPT
(Hutton et al., 1998) and PGRN (Baker et al., 2006)
genes, are associated with rigidity, akinesia and neuronal
loss in the substantia nigra, although symptom onset and
severity vary with each speciﬁc mutation (Foster et al.,
1997; Pickering-Brown et al., 2002; Le Ber et al., 2008;
Siuda et al., 2014; Baizabal-Carvallo and Jankovic,
2016). For example, an early PET study in three patients
with FTD associated with a chromosome 17 mutation
found severe reduction in presynaptic dopaminergic neu-
rons with normal D2 receptor levels in the striatum (Pal
et al., 2001). The hexanucleatide expansion in the C9orf72
gene on chromosome 9 is most typically associated with
FTD with amyotrophic lateral sclerosis (Rohrer et al.,
2015a), but up to half of patients have parkinsonism,
with decreased dopamine transporter levels in the basal
ganglia (Boeve et al., 2012; O’Dowd et al., 2012). Extra-
pyramidal symptoms are also seen with mutations in
CHMP2B, FUS, TARDBP, TREM2 and VCP (Siuda
et al., 2014; Baizabal-Carvallo and Jankovic, 2016). In
non-ﬂuent agrammatic variant PPA, there is frequent loss
of dopaminergic neurons in the striatum (Gil-Navarro
et al., 2013), which underlies the frequent progression of
motor symptoms in this disorder, and its clinical overlap
with CBS and PSP (Rohrer et al., 2010). Parkinsonism in
bvFTD and non-ﬂuent agrammatic variant PPA appears to
occur with all types of underlying pathology; tau (Hutton
et al., 1998), TDP-43 (Boeve et al., 2012) and FUS path-
ology (Deng et al., 2014) are all associated with motor
symptoms (Baizabal-Carvallo and Jankovic, 2016).
In addition to extrapyramidal motor features, degener-
ation of dopaminergic tracts, especially the mesocortical
pathway, could contribute to behavioural symptoms of
FTD. For example, D2 dopamine receptors are reduced in
the frontal lobes of patients with FTD (Frisoni et al., 1994)
(Fig. 1E), while CSF levels of dopamine and its metabolites
are reduced in some (Sjogren et al., 1998) but not all stu-
dies (Vermeiren et al., 2013). CSF levels of dopamine cor-
relate with agitation and caregiver burden in FTD (Fig. 1F)
(Engelborghs et al., 2008). However, these ﬁndings contrast
with a study that found higher dopamine levels in the pre-
frontal cortex at post-mortem (Vermeiren et al., 2016).
Such inconsistencies may result from technological or meth-
odological differences in tissue preparation or analysis, but
they may also reﬂect true heterogeneity in the FTD popu-
lation, especially in small post-mortem analyses.
Aggression, agitation and psychosis are distressing and
burdensome aspects of FTD. Antipsychotic medications
with dopaminergic receptor afﬁnity are often used to treat
them but patients can be extremely sensitive to the extra-
pyramidal side effects due to pretreatment nigrostriatal def-
icits (Pijnenburg et al., 2003). Atypical antipsychotics such
as quetiapine, olanzapine or clozapine cause fewer extra-
pyramidal side effects (Moretti et al., 2003b) while noting
that there is less evidence for their efﬁcacy in dementia.
In an open label, non-randomized study, olanzapine im-
proved behavioural ﬂuctuations, wandering and irritability
(Moretti et al., 2003b). An alternative strategy using me-
thylphenidate, a noradrenaline and dopamine reuptake in-
hibitor, reduced risk-taking behaviour in a small double-
blind, placebo-controlled study, but without effects on a
wide range of cognitive tasks (Rahman et al., 2006).
There is a case report of improved behaviour with methyl-
phenidate and bupropion (another noradrenaline and dopa-
mine reuptake inhibitor) in one patient with FTD (Goforth
et al., 2004). In addition to the uncertainty over dopamin-
ergic strategies to treat cognitive and behavioural symp-
toms in FTD, systematic evidence is lacking of the
efﬁcacy of levodopa or dopamine agonists to ameliorate
parkinsonism in FTD, with only case reports of beneﬁt in
some patients (Chow, 2002; Tsai and Boxer, 2014).
Progressive supranuclear palsy
In vivo and post-mortem studies show that the extrapyr-
amidal features of PSP are associated with a severe loss of
dopaminergic neurons and changes in dopamine receptors,
particularly D2 receptors. Pathological tau aggregates,
including neuronal tangles and glial inclusions, develop in
areas with a high density of dopaminergic neurons includ-
ing the substantia nigra and striatum (Litvan et al., 1996;
Hardman et al., 1997). There is marked loss of pigmented
dopaminergic neurons in the substantia nigra pars com-
pacta on examination post-mortem (Hardman et al.,
1997; Oyanagi et al., 2001). There is also loss of both
dopaminergic neurons and dopamine receptors in the stri-
atum (Baron et al., 1986; Kim et al., 2002; Oyanagi, 2002;
Im et al., 2006; Oh et al., 2012). Dopamine transporter
binding is reduced in the caudate, putamen and globus pal-
lidus at post-mortem (Warren et al., 2007b) and in vivo
(Fig. 2A) (Seppi et al., 2006). Dopamine levels are reduced
in the putamen, caudate nucleus, substantia nigra and
globus pallidus at post-mortem (Fig. 2C) (Ruberg et al.,
1985; Hornykiewicz and Shannak, 1994). In vivo PET
and single photon emission computed tomography
(SPECT) studies indicate reduced levels of D2 receptors in
the basal ganglia (Fig. 2D) (Brooks et al., 1992; Arnold
et al., 2002; Oyanagi, 2002) while post-mortem studies
show corresponding loss of D2 receptors in the putamen,
caudate and substantia innominata (Ruberg et al., 1985;
Pierot et al., 1988; Pascual et al., 1992; Landwehrmeyer
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and Palacios, 1994). One study reported higher D2 recep-
tor binding in the striatum compared with controls
(Warren et al., 2007a), which might represent receptor
upregulation in response to loss of presynaptic dopamin-
ergic neurons. In contrast D1 receptors appear relatively
well preserved (Pierot et al., 1988). There is also evidence
that the mesocortical pathway is impaired in PSP, with
degeneration of dopaminergic neurons in the ventral teg-
mental area (Murphy et al., 2008) and loss of dopamine
receptors in the frontal cortex, measured post-mortem with
3H-spiperone (Fig. 2B) (Ruberg et al., 1985). This is espe-
cially relevant to the often profound change in motivation
and apathy in PSP.
In contrast to Parkinson’s disease, motor symptoms in
typical clinical presentations of PSP (increasingly known
as progressive supranuclear palsy-Richardson’s syndrome,
or PSP-RS, to distinguish it from other phenotypes of PSP
pathology) (Ho¨glinger et al., 2017) typically do not re-
spond well to dopaminergic therapy. This may be because
in PSP there is loss of both dopaminergic neurons and re-
ceptors in the basal ganglia and cerebral cortex. This con-
trasts with Parkinson’s disease, in which predominant loss
of presynaptic nigrostriatal dopaminergic neurons is greater
than the relative preservation, or even upregulation, of
post-synaptic dopamine receptor densities (Olanow, 2004).
Corticobasal syndrome
CBS is caused by corticobasal degeneration (CBD) path-
ology in about 60% of cases, the remainder being due to
PSP, FTD, Alzheimer’s disease and other pathology (Boeve
et al., 1999; Alexander et al., 2014). Patients with CBD
have pathological neuroglial tau deposits, severe neuronal
loss and gliosis in the substantia nigra and striatum, typic-
ally with a history of extrapyramidal signs (Oyanagi et al.,
2001; Armstrong et al., 2013; Coyle-Gilchrist et al., 2016).
Despite this, the in vivo imaging evidence of dopaminergic
deﬁcits is inconsistent. Fluorodopa PET indicates presynap-
tic dopaminergic reductions in the caudate, putamen and
frontal cortex (Sawle et al., 1991; Nagasawa et al., 1996;
Laureys et al., 1999; Klaffke et al., 2006; Pirker et al.,
2015), but with wide variation and surprisingly no correl-
ation with disease duration or severity (Cilia et al., 2011).
Indeed some patients with autopsy-conﬁrmed CBD have
had a normal dopamine transporter SPECT scan despite
prominent parkinsonian features (Chaal and Rowe, 2013;
Figure 2 Dopamine deficits in PSP and CBS. (A) Ioflupane SPECT scan showing reduced pre-synaptic dopaminergic neurons in the striatum of
PSP and CBS compared to a normal scan. (B) Post-mortem dopamine receptor levels (measured by spiperone binding) are reduced in the frontal
cortex in PSP. Graph of data from Ruberg et al. (1985). Reprinted with permission from Wiley. (C) Dopamine levels are reduced in the caudate nucleus
and putamen in PSP. Graph of data from Ruberg et al. (1985). (D) D2 dopamine receptor levels (measured by 123I-iodobenzofuran SPECT) are reduced
in the striatum of PSP when compared with healthy controls and Parkinson’s disease. From Oyanagi (2002). Reprinted with permission from Wiley.
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Kaasinen et al., 2013), and D2 receptor levels can be un-
changed (Klaffke et al., 2006; Pirker et al., 2013). These
conﬂicting results may partly reﬂect the poor clinicopatho-
logical correlation of CBS with CBD (Boeve et al., 1999;
Cilia et al., 2011; Alexander et al., 2014). This is arguably
a greater problem in the older literature, which often used
CBD when referring to CBS, and therefore may include a
high proportion of Alzheimer’s disease in their cases. We
suggest that future studies of CBS need corollary patho-
logical or biomarker evidence to distinguish CBD and
non-CBD causes of CBS. The current evidence suggests a
complex and inconsistent relationship between nigrostriatal
dopamine deﬁciency and symptoms in patients with CBS,
but evidence is scarce in comparison to other disorders.
Noradrenaline
The locus coeruleus in the pons is the principle site of nor-
adrenaline synthesis in the brain and contains the soma of
noradrenergic neurons that project to the forebrain (Fig.
3A). Different subpopulations of neurons within the locus
coeruleus project to the orbitofrontal, medial prefrontal,
anterior cingulate and motor cortices (Chandler et al.,
2014). These noradrenergic pathways have an important
role in regulating the function of the prefrontal cortex
(McGaughy et al., 2008; Chandler et al., 2014), while in
contrast to dopamine, there is minimal noradrenergic in-
nervation of the striatum. Noradrenaline acts via a and b
G protein coupled receptor families, each of which com-
prise subtypes that have different responses to ligand bind-
ing (Sara, 2009). The effect of noradrenaline depends on
the relative densities of these receptors (Aston-Jones and
Cohen, 2005). For example, noradrenergic input to the
basal forebrain can promote arousal by activating cholin-
ergic neurons through a1 and b1 receptors and inhibiting
GABAergic neurons through a2 receptors (Schwarz and
Luo, 2015), while presynaptic auto-inhibitory a2 receptors
may paradoxically enhance noradrenergic transmission in
response to antagonists (Invernizzi and Garattini, 2004).
Noradrenaline is involved in regulating a range of behav-
iours including wakefulness, attention, memory and deci-
sion-making (Rowe et al., 1996; Sara, 2009; Dalley et al.,
2011; Aston-Jones and Waterhouse, 2016). In comparative
Figure 3 Noradrenergic deficits in FTD and PSP. (A) Schematic illustration of noradrenergic pathways. (B) MHPG/noradrenaline ratios,
indicative of catabolic noradrenergic turnover, are reduced in Brodmann areas 11, 22, 24 and 46 in FTD. From Vermeiren et al. (2016). Reprinted
with permission from the authors and IOS Press. The publication is available at IOS Press through http://dx.doi.org/10.3233/JAD-160320. (C)
Post-mortem brainstem tissue from control and PSP brains. There is a paler locus coeruleus suggesting loss of melatonin-containing noradrenergic
neurons. Courtesy of Kieran Allison, Cambridge Brain Bank. (D) Noradrenaline levels are reduced in the caudate (CN), putamen (PUT),
hippocampus (HTH) and parolfactory cortex (PAROLF). Serotonin levels are reduced in those areas as well as in the subthalamic nucleus (SN).
Dopamine levels are reduced in those areas as well as the globus pallidus externa (GPe) and interna (GPi). From Hornykiewicz and Shannak
(1994). Reprinted with permission from Springer.
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models, for example rats, limiting noradrenergic transmis-
sion results in impaired executive function (Newman et al.,
2008; Chandler et al., 2014) and increasing noradrenaline
levels reduces impulsivity (Robinson et al., 2008).
Computational and neurophysiological models suggest nor-
adrenergic pathways mediate salience and shift in attention
(Aston-Jones and Cohen, 2005).
Frontotemporal dementia
There is limited evidence for noradrenergic changes in FTD
but in many respects, the noradrenergic pathways appear
to be normal or near normal, relative to the marked deﬁcits
seen in other neurotransmitter pathways. For example,
neuropathological studies of FTD suggest the preservation
of cell density in the locus coeruleus, and noradrenaline
levels are normal or even elevated in the frontal lobe
(Vermeiren et al., 2016), despite the presence of patho-
logical tau inclusions (Nagaoka et al., 1995; Yang and
Schmitt, 2001; Brunnstro¨m et al., 2011; Irwin et al.,
2016). However, there may be reduced noradrenaline ca-
tabolism and turnover. For example, one study found low
3-methoxy-4-hydroxyphenylglycol (MHPG) to noradren-
aline ratios, a proposed marker of noradrenergic turnover,
in the frontal and temporal lobes, anterior cingulate, amyg-
dala and hippocampus (Fig. 3B) (Vermeiren et al., 2016). In
contrast, several studies show normal levels of noradren-
aline and MHPG in CSF (Sjogren et al., 1998; Engelborghs
et al., 2008; Vermeiren et al., 2013). However, in one of
these studies there was a correlation between CSF levels of
noradrenaline and disease severity, even though overall
levels were unchanged (Engelborghs et al., 2008). The
enzyme monoamine oxidase, which metabolizes noradren-
aline, is reduced in some areas of the brain (including the
temporal lobe) although levels are unchanged in the frontal
lobe (Sparks et al., 1991). This anatomical heterogeneity
may be one reason for the inconsistent reports of MHPG/
noradrenaline levels. However, an alternative explanation
is that the locus coeruleus receives inhibitory serotoninergic
innervation from the upper raphe nuclei (Yang and
Schmitt, 2001) such that the major loss of serotonergic
projections in FTD (see below) serves indirectly to increase
noradrenaline signalling to the frontal lobe.
Idazoxan is an a2 adrenoceptor antagonist that increases
synaptic noradrenaline levels by antagonism of inhibitory
autoreceptors on noradrenergic neurons. Idazoxan im-
proved attention, planning and problem-solving in a small
group of patients with FTD (Sahakian et al., 1994; Coull
et al., 1996). Looking ahead to candidate symptomatic
therapies, selective noradrenergic reuptake inhibitors such
as atomoxetine and reboxetine, or combined serotonin and
noradrenaline reuptake inhibitors like venlafaxine and
duloxetine, may provide better tolerated augmentation of
noradrenergic neurotransmission in FTD building on the
evidence of their safety and efﬁcacy in other disorders
(Wang et al., 2011; Cubillo et al., 2014; Kehagia et al.,
2014; Ye et al., 2015; Rae et al., 2016).
Progressive supranuclear palsy and
corticobasal syndrome
Evidence is emerging of an early noradrenergic deﬁcit in
PSP, with loss of noradrenergic neurons and low noradren-
aline levels in the basal ganglia. There is signiﬁcant path-
ology in the locus coeruleus with both tau deposition
(Dickson, 1999; Arnold et al., 2013), and neuronal loss
(Fig. 3C) (Hauw et al., 1994; Mori et al., 2002; Dickson
et al., 2010). A single post-mortem study also found
reduced levels of noradrenaline in the caudate and putamen
(Hornykiewicz and Shannak, 1994) (Fig. 3D), although
noradrenergic receptor density is normally low in the stri-
atum compared to cortex. These early and sometimes
severe noradrenergic changes may be directly linked to cog-
nitive and behavioural manifestations of PSP, such as rigid-
ity and impulsivity, analogous to the treatable
noradrenergic deﬁcit underlying aspects of impulsivity in
Parkinson’s disease (Kehagia et al., 2014; Rae et al.,
2016). In keeping with this, a double-blind cross-over
study of the a2 antagonist idazoxan showed improvement
in motor function in PSP (Ghika et al., 1991). However a
larger study with a more potent a2 antagonist (efaroxan)
found no effect (Rascol et al., 1998). Atomoxetine has been
shown to reduce impulsivity and executive deﬁcits in
Parkinson’s disease (Marsh et al., 2009; Kehagia et al.,
2014; Ye et al., 2015), but evidence is lacking in PSP.
Evidence is also lacking for noradrenergic changes in
CBS, although tau pathology is present in the locus coer-
uleus (Dickson, 1999).
Serotonin
Serotonin (5-HT) is synthesized mainly by two groups of
neurons in the raphe nuclei in the brainstem, which project
widely (Fig. 4A) (Charnay and Le´ger, 2010). The rostral
group, comprising 85% of serotonergic neuron cell bodies,
project to the cerebral cortex, thalamus, hypothalamus and
basal ganglia (Hornung, 2003). The caudal group project
mainly to the brainstem and spinal cord (Hornung, 2003).
With these widespread projections, serotonin regulates
many higher brain functions related to cognitive control,
learning, and affect (Harvey, 2003; Ciranna, 2006; Canli
and Lesch, 2007; Artigas, 2013). There are seven different
serotonin receptor families (5-HT1–7), which are neuromo-
dulatory G protein coupled receptors except for the 5-HT3
receptor family, which includes ligand-gated ion channels
(Barnes and Sharp, 1999; Southan et al., 2016). To add to
this complexity, genetic polymorphisms within a receptor
subtype (Barnes and Sharp, 1999) and presynaptic trans-
porter (Porcelli et al., 2012), inﬂuence serotonergic
function.
Serotonin receptors are among the most complex and
varied of neurotransmitter receptors, and while there is
clear evidence of serotonergic deﬁcits in FTLD, studies to
date mainly lack a detailed breakdown of receptor
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subtypes, or focus on 1A and 2A receptors. Serotonin has
important roles in synaptic plasticity and as a neuromodu-
lator of the direct effects of other neurotransmitters (Celada
et al., 2013). For example, serotonin inhibits dopamine re-
lease and modulates glutamate and GABA transmission
(Ciranna, 2006). In the hippocampus serotonin receptors
reduce glutamate and stimulate GABA from inhibitory
interneurons, reducing long term potentiation (Ciranna,
2006). In the frontal cortex glutamate release is inhibited
by serotonin whereas in the prefrontal cortex serotonin en-
hances glutamate transmission (Dawson et al., 2001;
Ciranna, 2006). This suggests that FTLD-induced serotonin
Figure 4 Serotonergic deficits in FTD and PSP. (A) Schematic illustration of serotonin pathways. (B) 5-HT1 and 2A receptor density is
reduced in the frontal and temporal lobe in FTD. Graph of data from Bowen et al. (2008). Reprinted with permission of the authors and Springer.
(C) Effect of 5-HTTLPR genotype on brain perfusion in FTD patients. Comparison of long (L/L) versus short (S/S) carriers at the same disease
stage showing reduced perfusion of some areas of the frontal lobe in L/L carriers. From Premi et al. (2015). Reprinted with permission from
Elsevier. (D) Presynaptic serotonergic neurons (measured by citalopram binding to post-mortem tissue) are reduced in the frontal and insular
cortices in PSP. Graph of data from Chinaclia and Landwehrmeyer (1993). Reprinted with permission from Elsevier. (E) 5-HT2A receptor PET
binding is increased bilaterally in the striatum and substantia nigra compared with controls. In the same study (F) disease severity positively
correlated with 5-HT2A binding potential in the striatum. From Stamelou et al. (2009). Reprinted with permission from Wiley.
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deﬁciency could cause widespread cognitive, motor and af-
fective symptoms, directly and through the disruption of its
modulation of other systems.
Frontotemporal dementia
Serotonin dysfunction is a signiﬁcant contributor to the be-
havioural and cognitive symptoms seen in bvFTD (Huey
et al., 2006; Hughes et al., 2015). Reductions in serotonin
transmission or postsynaptic receptor densities are asso-
ciated with several symptoms seen in FTD including aggres-
sion, impulsivity, increased appetite and depression (Huey
et al., 2006). At post-mortem examination, 5HT1A and 2A
receptors are reduced in the frontal and temporal lobes and
the hypothalamus (Fig. 4B) (Sparks and Markesbery, 1991;
Francis et al., 1993; Procter et al., 1999; Bowen et al.,
2008). In vivo PET studies corroborate the post-mortem
ﬁndings with the 5-HT2A receptor binding potential
reduced in the midbrain and medial frontal cortex
(Franceschi et al., 2005) and the 5-HT1A binding potential
reduced across all cortical areas (Lanctoˆt et al., 2007).
Evidence for actual serotonergic neuronal cell loss is less
conclusive. One post-mortem study found loss of neurons
in the raphe nucleus and their projections to the cerebral
cortex, which correlated with disease duration (Yang and
Schmitt, 2001). There is also pathological tau deposition in
the raphe nuclei (Irwin et al., 2016). This contrasts with
other studies that report no change in imipramine binding,
proposed as a measure of presynaptic serotonergic
terminals (Sparks and Markesbery, 1991), while post-
mortem biochemical assays of serotonin are normal or ele-
vated in FTD (Bowen et al., 2008; Vermeiren et al., 2016)
and CSF measures of serotonin and its metabolites are un-
changed (Engelborghs et al., 2008). Nonetheless, CSF
homovanillic acid/5-hydroxyindoleacetic acid (HVA/5-
HIAA) levels (a proposed marker of the serotonergic modu-
lation of dopaminergic neurotransmission) correlate with
aggressive behaviour in FTD (Engelborghs et al., 2004,
2008). 5-HIAA/5-HT ratios (a proposed marker of seroto-
nergic turnover) are also lower in FTD compared to con-
trols in the frontal and temporal lobes (Vermeiren et al.,
2016). It is possible that these apparent inconsistencies be-
tween biochemical assays and receptor or neuronal markers
result from different stages of serotonergic cell loss and
downstream functional compensation. To test this hypoth-
esis would require the comparison of methods within the
same pathological cohort, preferably one that includes pa-
tients with a wide range of neurocognitive severity.
There appears to be an association between FTD and
length polymorphism in the gene promotor S(5-HTTLPR)
of the serotonin transporter gene (SLC6A4) which suggests
serotonin may be involved in the pathogenesis of FTD. A
short allele (5-HTTLPR-s) was associated with a greater
susceptibility to FTD in one study (Albani et al., 2008)
although this was not replicated (Yokoyama et al., 2015).
The 5-HTTLPR variant also affects brain atrophy in FTD.
Patients with a long 5-HTTLPR allele have correspondingly
greater atrophy and lower perfusion at equivalent disease
stages (Fig. 4C) (Premi et al., 2015) while the short allele is
associated with more atrophy in the left inferior frontal
gyrus and less in the right temporal lobe (Yokoyama
et al., 2015). The long allele may have a protective effect
on cognitive presentation but is not associated with better
prognosis (Borroni et al., 2010).
In bvFTD there are reduced neurophysiological markers of
inhibitory control and prefrontal cortical function, which are
restored with the selective serotonin reuptake inhibitor cita-
lopram in a placebo-controlled double-blind assessment
(Hughes et al., 2015). Several open label studies without pla-
cebo-control have shown improvement in behavioural symp-
toms with serotonergic drugs. For example, citalopram
reduced disinhibition, irritability and depression (Herrmann
et al., 2012) and improved Frontal Assessment Battery test
scores (Herrmann et al., 2012) and inappropriate sexual be-
haviour (Anneser et al., 2007). Paroxetine improved behav-
ioural symptoms in an open label study (Moretti et al.,
2003a) but this was not supported by a subsequent pla-
cebo-controlled blinded study (Deakin et al., 2004).
Trazodone may improve behavioural symptoms in bvFTD
based on a randomized control cross-over study (Lebert
et al., 2004). Interestingly, trazodone differs from selective
serotonin reuptake inhibitors (SSRIs): it is an antagonist of
a range of serotonin receptors apart from 5HT1A where it is
an agonist, and it inhibits the serotonin transporter. A meta-
analysis of antidepressants in FTD showed a combined mean
reduction of 15 points on the Neuropsychiatric Inventory,
noting, however, that the evidence was mainly from small,
non-placebo controlled trials (Huey et al., 2006).
Progressive supranuclear palsy and
corticobasal syndrome
Pathological tau inclusions are found post-mortem in the
raphe nuclei with PSP (Revesz et al., 1996) while presynap-
tic serotonergic neurons are reduced in the caudate nucleus,
frontal and temporal cortex (Fig. 4D) (Chinaclia and
Landwehrmeyer, 1993). Serotonin levels were not signiﬁ-
cantly reduced in one post-mortem study (Hornykiewicz
and Shannak, 1994). PET and post-mortem studies have
both shown upregulation of 5-HT1B and 2A receptors in
the substantia nigra and striatum (Fig. 4E) (Castro et al.,
1998; Stamelou et al., 2009), which might represent com-
pensation for loss of presynaptic serotonergic neurons. This
upregulation correlated with severity of motor impairment
(Fig. 4F) (Stamelou et al., 2009), but information on the
correlation with cognitive, affective or associative functions
is also needed.
There have been case reports of patients with PSP show-
ing some improvements in motor function with an SSRI
(Miyaoka et al., 2002), and anecdotal reports of serotoner-
gic reuptake inhibition as an effective treatment for emo-
tional lability (Rittman et al., 2016). Overall there is not
strong evidence for the efﬁcacy of serotonergic drugs in PSP
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(Stamelou and Ho¨glinger, 2016). This lack of evidence may
be because studies have focussed on depression and anxiety
as outcomes of treatment, rather than impulsivity, disinhib-
ition or cognitive change (Rittman et al., 2016).
There is neuronal loss and gliosis in the raphe nucleus in
CBD (Gibb et al., 1989). However in vivo data are lacking
on the serotonergic pathways and receptor density in CBS,
and there are no systematic trials of serotonin reuptake
inhibitors.
Acetylcholine
Acetylcholine is neuromodulatory on many areas of the
forebrain (Everitt and Robbins, 1997), and inﬂuences a
wide range of cognitive functions including attention,
memory and emotion, but also motor control, through cor-
tical and subcortical transmission in the cortico-striato-tha-
lamocortical circuits (Picciotto et al., 2012). The major
cholinergic inputs to the cerebral cortex originate in the
nucleus basalis of Meynert and adjacent nuclei in the
basal forebrain (Fig. 5A) (Selden, 1998). Two other cholin-
ergic nuclei in the brainstem, the pedunculopontine and
lateral dorsal tegmental nuclei, project to the thalamus.
Acetylcholine acts on two main receptor classes in the
brain; muscarinic G protein coupled receptors (M1–5)
and nicotinic ligand-gated ion channels (Picciotto et al.,
2012). Cholinergic receptors can have excitatory or inhibi-
tory effects depending on their subtype and pre- versus
postsynaptic location (Picciotto et al., 2012).
Cholinergic drugs are in widespread use clinically, al-
though not speciﬁcally in FTLD. For example, anti-cholin-
ergic drugs reduce tremor and dystonia in movement
disorders (Rifkin et al., 1978), although they can cause
impairments in learning and memory (Everitt and
Robbins, 1997). The loss of cholinergic neurons and
reduced choline acetyltransferase in Alzheimer’s disease
(Francis et al., 1999) lies behind the widespread use of
cholinesterase inhibitors to enhance cholinergic transmis-
sion and thereby alleviate cognitive symptoms in
Alzheimer’s disease (Rogers et al., 1998). This cholinergic
hypothesis has led to research into the role of cholinergic
therapies in other dementias, including syndromes arising
from FTLD.
Frontotemporal dementia
Cholinergic pathways are affected in FTD but not to the
same extent as in Alzheimer’s disease. While there is some
loss of cholinergic neuronal markers in the nucleus basalis,
overall cholinergic pathways to the cortex appear un-
affected. Choline acetyltransferase, the enzyme for the syn-
thesis of acetylcholine, can be used as a marker of
presynaptic cholinergic neuron integrity. Post-mortem
levels of choline acetyltransferase are reduced in the nucleus
basalis of Meynert and the hypothalamus but are normal in
the frontal, temporal and parietal lobes (Wood et al., 1983;
Hansen et al., 1988; Sparks and Markesbery, 1991; Procter
et al., 1999). Acetylcholinesterase, which catalyses the
breakdown of acetylcholine, is predominantly located on
the presynaptic cholinergic neurons. Levels are reduced in
the nucleus basalis at post-mortem (Sparks and
Markesbery, 1991) but have been normal in the thalamus
and cerebral cortex when measured in vivo with 11C-MP4A
PET (Fig. 5B and C) (Hirano et al., 2010) or at
post-mortem (Meier-Ruge et al., 1984; Sparks and
Markesbery, 1991).
Studies are inconsistent on cholinergic receptors in
bvFTD. 123IQNB SPECT imaging of two patients with
Pick’s disease indicated reduced muscarinic receptor density
in the frontal and temporal cortex (Weinberger et al., 1991)
consistent with autoradiography in a case report (Yates
et al., 1980). In contrast two studies found no signiﬁcant
change in muscarinic receptor density post-mortem (Wood
et al., 1983; Procter et al., 1999).
There is evidence of a cholinergic deﬁcit in primary pro-
gressive aphasia. In patients with semantic dementia there
was loss of muscarinic receptors in the temporal lobe
(Odawara et al., 2003). Disproportionate atrophy of the
basal forebrain nuclei was identiﬁed in a high resolution
MRI study, most evidently in the semantic variant, and
to a lesser extent the non-ﬂuent variant (Teipel et al.,
2016). This is relevant in view of the evidence that the
frontotemporal language networks of a healthy brain re-
ceive signiﬁcant cholinergic inputs (Amunts et al., 2010).
The logopenic variant had minimal structural change, des-
pite its strong clinicopathological correlation with
Alzheimer’s disease.
Despite the possible cholinergic deﬁcits in bvFTD and
PPA, cholinesterase inhibitors do not convincingly improve
cognitive function. An open label non-randomized study
found that behavioural changes improved with rivastig-
mine, in comparison to a group that took antipsychotics
and benzodiazepines (Moretti et al., 2004). In contrast
bvFTD patients taking donepezil had worsening disinhib-
ition and compulsive behaviour (Mendez et al., 2007).
A randomized, double-blind trial of galantamine versus pla-
cebo found no effect on cognitive function or activities of
daily living (Kertesz et al., 2008).
Progressive supranuclear palsy and
corticobasal syndrome
There are marked cholinergic deﬁcits in PSP, which may
contribute not only to cognitive impairment but also pos-
tural instability via the pedunculopontine nucleus (Jellinger,
1988; Warren et al., 2005). There is loss of cholinergic
neurons and their presynaptic terminals in many subcor-
tical regions in PSP. Choline acetyltransferase is reduced
in the nucleus basalis of Meynert, midbrain nuclei and
pedunculopontine nucleus (Fig. 5D) (Juncos et al., 1991;
Javoy-Agid, 1994; Kasashima and Oda, 2003) as well as
the putamen, caudate and pallidum (Ruberg et al., 1985;
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Pierot et al., 1988; Javoy-Agid, 1994). Presynaptic acetyl-
choline transporters are reduced in the putamen and sub-
stantia nigra, while sparing the globus pallidus and cerebral
cortex (Fig. 5F) (Suzuki et al., 2002). 123I-IBVM SPECT,
which binds to acetylcholine transporters, reveals reduced
signal in the thalamus of PSP patients (Fig. 5E) (Mazere
et al., 2012) and PET studies show reduced acetylcholin-
esterase binding in the pons, basal ganglia and thalamus
(Shinotoh et al., 1999; Gilman et al., 2010; Hirano et al.,
2010).
There is loss of cholinergic projections from the brain-
stem (pedunculopontine and laterodorsal tegmental nuclei)
Figure 5 Cholinergic deficits in FTD, PSP and CBS. (A) Schematic illustration of cholinergic pathways. (B and C) 11C-MP4A PET, a
measure of acetylcholinesterase activity, in healthy controls, CBS, PSP and FTD. Cortical k3 (a measure of PET ligand binding) is reduced in CBS
and PSP but not FTD. Thalamic mean k3 is reduced in PSP but not CBS or FTD. From Hirano et al. (2010). Reprinted with permission from Oxford
University Press. (D) Quantitative estimation of choline acetyltransferase (ChAT) positivity rate (%) in the nucleus basalis of Meynert (nBM),
laterodorsal tegmental (LdtgN) and pedunculopontine tegmental (PptgN) nuclei. From Kasashima and Oda (2003). Reprinted with permission of
Springer. (E) SPECT of acetylcholine transporter. MNI = MRI template; HS = healthy subject. Specific binding in the striatum, thalamus and
pedunculopontine nucleus extracted by subtracting reference from region of interest binding. Binding is lower in the thalamus and pedunculo-
pontine nucleus. From Mazere et al. (2012). Reproduced with permission from the Radiological Society of North America. (F) Autoradiogram of
brain tissue from a healthy control (NC) and PSP. 3H-vesamicol binding to acetylcholine transporter (VAChT). There is reduction in binding in the
putamen (Put) and substantia nigra pars compacta (SNc). Rn = red nucleus. Image intensity converted to pseudocolour representation according
to key. From Suzuki et al. (2002). Reproduced with permission from Wolters Kluwer.
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to the thalamus (Hirsch et al., 1987; Jellinger, 1988;
Kasashima and Oda, 2003). The pedunculopontine loss is
especially relevant to the impairment of movement, gait
and muscle tone in PSP (Benarroch, 2013). Deep brain
stimulation of the pedunculopontine nucleus has been re-
ported to improve PSP motor symptoms in selected cases,
but deﬁnitive trials are lacking (Hazrati et al., 2012;
Servello et al., 2014). One study reported that acetylcholine
receptors are relatively well preserved in the striatum
(Ruberg et al., 1985) while other studies report a reduction
in muscarinic and nicotinic receptors in the striatum
(Landwehrmeyer and Palacios, 1994; Warren et al.,
2007b). With such small series, and variable methods, it
is unclear if technical or phenotypic differences account
for these inconsistencies.
There is also some limited evidence for cholinergic def-
icits in the cerebral cortex. Acetyltransferase levels are
reduced in frontal cortex of PSP patients compared with
controls both at post-mortem and with in vivo PET ima-
ging (Ruberg et al., 1985; Javoy-Agid, 1994; Hirano et al.,
2010). However, cortical muscarinic receptor levels appear
to be unaffected in PSP, with levels similar to controls in
PET studies (Ruberg et al., 1985; Asahina et al., 1998).
In clinical practice, cholinergic blockade with hyoscine is
sometimes used for sialorrhoea and drooling, but it may
worsen gait and memory in PSP (Litvan et al., 1994).
Despite this deleterious effect of anti-cholinergic medication,
the converse ‘pro-cholinergic’ treatment by cholinesterase
inhibitors is typically ineffective (Stamelou and Ho¨glinger,
2016). A case series of rivastigmine in ﬁve patients found
that it improved working memory, memory and verbal ﬂu-
ency but worsened motor function (Liepelt et al., 2010). A
randomized, placebo-controlled crossover study of donepe-
zil showed no effect on quality of life, Progressive
Supranuclear Palsy Rating Scale or global cognitive function
(Litvan et al., 2001). This study did ﬁnd a slight improve-
ment in one memory task but also worsened motor activ-
ities of daily living (Litvan et al., 2001). Interestingly, the
syndrome of pure akinesia and gait freezing, now recog-
nized as a prodromal variant of PSP (Ho¨glinger et al.,
2017) has been reported to improve after cholinesterase in-
hibition in an open case series (Kondo, 2006). Despite this
encouraging study, replication in a placebo controlled trial
is awaited.
In a post-mortem study of a single case of CBD the
number of cholinergic acetyltransferase positive neurons in
the nucleus basalis of Meynert was reduced (Kasashima and
Oda, 2003). This was replicated in vivo, with reduced
acetylcholinesterase levels in the frontal, parietal and occipi-
tal cortex (Hirano et al., 2010). There is insufﬁcient data on
cholinergic treatment of patients with CBS, although it
should be noted that 20–40% of patients with CBS have
Alzheimer’s-type pathology not CBD (Boeve et al., 1999;
Alexander et al., 2014). It is plausible, but not proven,
that the Alzheimer pathology cases of CBS would respond
better to cholinesterase inhibitors despite appearing similar
to CBD cases in other clinical features. We therefore
anticipate that clinical trials of CBS will stratify treatment
according to biomarkers, such as amyloid PET imaging or
CSF, to distinguish CBD from Alzheimer’s disease aetiology.
Glutamate
Glutamate is the principle excitatory neurotransmitter in the
brain. Glutamate acts on fast, short acting ionotropic recep-
tors and slower but longer acting metabotropic glutamate
receptors (mGluR) (Meldrum, 2000). The three main iono-
tropic glutamate receptors are named after the selective
agonists N-methyl D-aspartate (NMDA), a-amino-3-hy-
droxyl-5-methyl-isoxazolepropionic acid (AMPA) and kain-
ite (Meldrum, 2000). Glutamate has an important role in
learning and memory formation. For example, NMDA re-
ceptors in the hippocampus regulate long term potentiation
(Morris et al., 1986; Rowland et al., 2005) while sustained
activation of the dorsolateral prefrontal cortex during work-
ing memory requires NMDA stimulation (Wang et al.,
2013). NMDA receptor antagonists impair attention, reac-
tion time, processing speed and working memory in healthy
humans (Malhotra et al., 1996; Newcomer et al., 2000),
and may exacerbate psychotic symptoms (Gilmour et al.,
2012). Glutamate signalling through NMDA receptors is
required to create and maintain gamma oscillations (Carle´
et al., 2011), which support many higher cognitive functions
(Lange et al., 1997; Bartos et al., 2007; Williams and Boksa,
2010; Gaetz et al., 2012; Gorelova et al., 2012).
While glutamatergic transmission is essential for cogni-
tion, excessive glutamatergic transmission may also be
harmful, promoting excitotoxic neuronal death (Mark
et al., 2001) that contributes to neurodegeneration in
models of Alzheimer’s disease (Danysz et al., 2000; Kalia
et al., 2008). It is possible that FTLD is similarly affected.
Functionally, continuous overactivation of NMDA recep-
tors alters the efﬁcacy of information processing by redu-
cing the sensitivity of neural networks and impairing their
ability to detect a relevant signal from upstream neurons
(Danysz et al., 2000). Memantine is a low afﬁnity NMDA
receptor antagonist and selectively blocks pathological
tonic NMDA receptor activation (associated with amyloid
plaques) without preventing NMDA-mediated synaptic
transmission. In addition to potential symptomatic effects
on cognition (Reisberg et al., 2003), it might therefore also
reduce chronic glutamatergic excitotoxicity (Danysz and
Parsons, 2012).
Frontotemporal dementia
There is preclinical and clinical evidence that glutamate is
important in the pathogenesis of FTD. For example, trans-
genic mice that express pathological human tau have repeti-
tive and disinhibited behaviour, coupled with NMDA
receptor hypofunction (Warmus et al., 2014). Treatment
with an NMDA agonist restores their behaviour.
Transgenic mice expressing mutations in the FTD-
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associated gene CHMP2B, have altered AMPA receptor
composition (Gascon et al., 2014), with impaired sociabil-
ity, which can be reversed if normal AMPA receptor com-
position is restored (Gascon et al., 2014). Mouse models
expressing pathological human tau suggest glutamate
mediated excitotoxicity could accelerate neuronal loss in
tauopathies such as FTD (Decker et al., 2016). These pre-
clinical studies raise the possibility that pharmacological
glutamatergic treatments might reduce symptom severity
and improve prognosis.
In patients, glutamatergic pyramidal neurons are reduced
in the thalamus, frontal and temporal cortex (Ferrer, 1999).
Magnetic resonance spectroscopy of patients with FTD has
found glutamate/glutamine levels are reduced in the frontal
and temporal lobes (Fig. 6A) (Ernst et al., 1997; Sarac
et al., 2008). There is an inverse correlation between CSF
glutamate levels and verbal agitation (Vermeiren et al.,
2013).
Both ionotropic and metabotropic glutamate receptors
are affected in FTD. For example, AMPA and NMDA
receptor densities are reduced in the frontal and temporal
lobes of patients at post-mortem (Francis et al., 1993;
Procter et al., 1999; Bowen et al., 2008), while AMPA
receptor composition is also abnormal (Fig. 6B) (Gascon
et al., 2014). Using the ligand 11C-ABP688, PET of pa-
tients with bvFTD found reduced availability of metabo-
tropic glutamate receptors (mGluR5) in the frontal and
temporal lobes, basal ganglia and thalamus (Leuzy et al.,
2016). However, one study found that post-mortem levels
of metabotropic glutamate receptors type 1 and 5
(mGluR1 and 5) are increased in the frontal cortex
(Dalfo et al., 2005).
A phase II randomized placebo-controlled trial of mem-
antine showed no beneﬁt in patients with bvFTD (Boxer
et al., 2013). A double-blind placebo-controlled crossover
trial of memantine in PPA was also negative (Johnson
et al., 2010). However, these studies were not powered
to detect small treatment effects. While there may be no
true beneﬁt, it remains possible that small treatment ef-
fects exist which would be ampliﬁed if other neurotrans-
mitter deﬁcits were also normalized, in particular
GABAergic impairments. The GABA–glutamate inter-
action is of particular relevance because it supports pre-
cisely tuned oscillatory dynamics of neural circuits for
cognition (Bastos et al., 2012).
Progressive supranuclear palsy and
corticobasal syndrome
Loss of glutamatergic neurons in the basal ganglia may
partly explain why dopaminergic therapy is ineffective in
PSP. Glutamate modulates dopamine release and loss of
glutamatergic neurons may prevent patients compensating
for dopaminergic neuron loss (Lange et al., 1997).
Glutamatergic neurons from the caudal intralaminar
nuclei that form the thalamostriatal pathway are reduced
in PSP (Fig. 6C) (Henderson et al., 2000). However, the
severity of this neuronal loss does not correlate with disease
duration or severity (Henderson et al., 2000). In contrast,
NMDA receptor levels are preserved in the frontal and
temporal lobes and striatum (Holemans et al., 1991).
Glutamatergic over-activity is implicated in Parkinson’s
disease and by analogy has been considered a candidate
mechanism of accelerated neurodegeneration in PSP
(Lange et al., 1997). Amantadine is an NMDA receptor
antagonist that is often used to treat motor symptoms
(Kompoliti et al., 1998; Stamelou and Ho¨glinger, 2016),
although there is no randomized controlled trial evidence
of efﬁcacy in PSP. Gabapentin has complex pharmaco-
dynamics and in part acts by increasing GABA and redu-
cing glutamate levels (Sills, 2006). A randomized blinded
trial of gabapentin in 14 patients found no effect on motor
function but improved outcome in anti-saccade control
(Poujois et al., 2007), which is associated with frontal
lobe integrity (Mirsky et al., 2011; Perneczky et al.,
2011) and commonly impaired in PSP (Garbutt et al.,
2008; Zhang et al., 2016). There are no reports of post-
mortem or in vivo glutamate measurements in CBS.
Gamma-aminobutyric acid
GABA is the predominant inhibitory neurotransmitter in
the brain, formed by glutamate decarboxylase conversion
of glutamate to GABA in interneurons. There are two
classes of GABA receptors: GABAA ligand-gated ion chan-
nels and GABAB G protein coupled neuromodulatory re-
ceptors. GABAergic inhibitory neurons dampen and
balance excitation within neural circuits, but do more
than simply counteract excitatory glutamatergic neurons.
They have a key role in the regulation of oscillatory dy-
namics, including the generation of gamma oscillations and
regulation of the magnitude and frequency of these oscilla-
tions (Owens and Kriegstein, 2002; Mann and Paulsen,
2007; Buzsa´ki and Wang, 2012). This is essential for coor-
dinating information transfer and information processing in
the brain (Fries, 2009; Bastos et al., 2012). Increasing syn-
aptic GABA levels increases gamma power during cognitive
control tasks (Frankle et al., 2009) whereas inhibiting
GABA receptors reduces gamma oscillatory power and im-
pairs inhibition and working memory (Hines et al., 2013).
Gamma oscillations correlate with GABA concentrations
(as measured by magnetic resonance spectroscopy) in the
visual (Muthukumaraswamy et al., 2009), primary motor
(Gaetz et al., 2011) and dorsolateral prefrontal cortex
(Kujala et al., 2015) while GABAA receptor density (as
measured by ﬂumazenil-PET) correlates with gamma fre-
quency and magnitude (Kujala et al., 2015). Impaired
GABA neurotransmission has been implicated in a
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number of brain disorders including schizophrenia
(Gonzalez-Burgos et al., 2011) and Huntington’s disease
(Reynolds and Sally, 1990) as well as the syndromes asso-
ciated with FTLD.
Frontotemporal dementia
The subgroup of GABAergic neurons that bind calbindin-
D28k are reduced in upper neocortical layers of the frontal
and temporal cortex in FTD (Ferrer, 1999), especially in
layers II and III (Fig. 6E) (Ferrer, 1999). However, in the
same study, the subgroup of GABAergic basket and chande-
lier neurons that bind parvalbumin were preserved (Ferrer,
1999). The superﬁcial layers II and III are the main source of
cortico-cortical feedforward efferent projections and receive
feedback projections from deep layers. Gamma oscillations
and coherence are reduced between the frontal lobes of pa-
tients with bvFTD (Hughes et al., 2013), which may relate
to loss of cortical feedforward information processing and
cognitive decline (Mann and Paulsen, 2007). GABA concen-
trations are also decreased in the basal ganglia in bvFTD
(Kanazawa et al., 1988). GABAergic approaches to
treatment of FTD symptoms warrant further investigation,
but evidence of their clinical efﬁcacy is currently lacking.
Progressive supranuclear palsy and
corticobasal syndrome
GABAergic interneurons are reduced in PSP. A post-
mortem study found a 50–60% decrease in the number
of GABAergic neurons (estimated from the number express-
ing glutamic acid decarboxylase mRNA, by in situ hybrid-
ization) in the caudate nucleus, putamen, ventral striatum
and pallidum (Fig. 6D) (Levy et al., 1995). Binding to
GABAA receptors is reduced in the globus pallidus but
preserved in the striatum (Landwehrmeyer and Palacios,
1994; Suzuki et al., 2002). A ﬂumazenil-PET study
showed loss of GABAA receptors compared with controls
(Fig. 6F) (Foster et al., 2000).
There are case reports of GABA receptor agonists im-
proving speech, eye movements, akinesia and rigidity in
PSP (Daniele et al., 1999; Cotter et al., 2010; Dash,
2013; Chang and Weirich, 2014), but in the authors’
Figure 6 Glutamate and GABA deficits in FTD and PSP. (A) Mean metabolite concentrations using magnetic resonance spectroscopy.
Glutamine–glutamate concentrations are reduced in the frontal cortex of FTD. Graph of data from Ernst et al. (1997). Reprinted with permission
from the authors and the Radiological Society of North America. (B) Post-mortem glutamatergic receptor binding in FTD. Binding to NMDA and
AMPA receptors is reduced in the frontal and temporal lobes. From Procter et al. (1999). Reprinted with permission from S. Karger AG.
(C) Neuron number in two thalamic nuclei [parafascicular (Pf) and centromedian (CM)] that contain glutamatergic neurons is reduced in PSP
compared with controls. Adapted from Henderson et al. (2000), with permission from the authors and Oxford University Press. (D) Numbers of
GABAergic neurons (measured by glutamic acid decarboxylase mRNA expression) in the striatum and pallidum in controls and PSP patients.
There is significant reduction in striatal GABAergic neurons in patients. Graph of data from Levy et al. (1995), reprinted with permission from the
authors and Wolters Kluwer. (E) Calbindin immunohistochemistry of GABAergic cells in the frontal cortex of FTD and control brains. From
Ferrer (1999). Reproduced with permission from Karger. (F) 11C-flumazenil PET binding to benzodiazepine receptors in healthy controls (N), PSP
and the group difference in cortical and subcortical areas. From Foster et al. (2000). Reproduced with permission from Wolters Kluwer.
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experience this phenomenon is very uncommon and there
are no randomized placebo controlled studies. There are no
reports of post-mortem or in vivo assessments of GABA in
CBS.
Towards better symptomatic
treatment in frontotemporal
lobar degeneration
Despite their overlapping clinical phenotypes and patho-
logical features, the major clinical syndromes associated
with FTLD have different neurotransmitter deﬁcits (sum-
marized in Table 1). Restoring these deﬁcits, individually
or in combination, has the potential to improve cognitive,
behavioural and motor symptoms. However, the evidence
base for therapeutic effects is dominated by small, open-
label studies in unstratiﬁed populations.
To summarize the evidence for selective deﬁcits, FTD
causes loss of serotonergic and dopaminergic neurons and
receptor densities, whilst noradrenergic and cholinergic
pathways are relatively preserved. There is loss of both
glutamatergic and GABAergic neurons but the functional
consequence of their deﬁcits is unclear, in part because of
the complex and dynamic interaction between GABAergic
and glutamatergic neurons in cortical circuits. In PSP, the
most evident neurotransmitter deﬁcits are dopaminergic,
noradrenergic and cholinergic, whilst serotonergic projec-
tions appear to be relatively preserved. There is evidence
of a glutamatergic and GABAergic deﬁcit, which provide
potential avenues for non-dopaminergic therapy. There is
limited evidence on the neurotransmitter deﬁcits in CBS,
with some evidence of deﬁcits in both cholinergic and
dopaminergic pathways.
Although clinical trials and cases series have not shown
consistent beneﬁts from the modulation of neurotransmit-
ters in FTLD syndromes, this may be due to weaknesses in
research methodology rather than a true lack of effect. For
example, many studies use what would now be considered
as outdated and inaccurate diagnostic criteria, which re-
duces the applicability to contemporary patient popula-
tions. Many clinical studies are open-labelled and in small
series, sometimes fewer than 10 patients, giving little power
to detect beneﬁts, let alone guide therapeutic stratiﬁcation.
There is a paucity of replication studies, and where studies
contain a ‘conceptual replication’, details in research meth-
odology confound the interpretation of seemingly conﬂict-
ing results. Much of the research comes from post-mortem
brain tissue, which has the advantage of providing concur-
rent pathological validation of the disorder. However, post-
mortem studies have tended to use small series (n510),
and by the nature of post-mortem material, they cannot
provide insights into the early or sequential changes in
neurotransmitter systems. Future work will beneﬁt from
longitudinal and in vivo studies, exploiting advances in
PET ligands (Finnema et al., 2015), ultra-high ﬁeld MRI
and spectroscopy (Agarwal and Renshaw, 2012), and CSF
biomarkers. Early PET studies of necessity used non-spe-
ciﬁc ligands, which may not correspond to the receptor
speciﬁcities of psychopharmacological agents. This is not
to criticise either body of work, but it does impair the
direct comparison of imaging and pharmacological studies,
even where comparable patient groups are studied.
Similarly, future preclinical studies would beneﬁt from
within-sample comparisons of different methods, seeking
not only cross-validation of biochemical or receptor
assays, but also the relationship between different meas-
ures, for example neuronal loss, receptor density, and bio-
chemical turnover of a neurotransmitter. Such cross-modal
studies would provide a powerful resource to model disease
progression and functionally relevant compensatory
changes in FTLD.
Further research is required into the effect of FTLD on
different neurotransmitter receptors and their subtypes, not
only to guide candidate drug selection, but also to deter-
mine the progression of changes from early to late stage
disease. Without this detailed knowledge, there is a risk
that a given drug may be effective at one stage of disease
but be counterproductive at another. Such non-linear dose-
response effects are common in dopaminergic treatments of
Parkinson’s disease (Cools, 2006; Rowe et al., 2008), but
the principal of ‘U-shaped’ responses to drug treatment also
affect serotonergic (Macoveanu et al., 2013; Hughes et al.,
2015) and noradrenergic drugs (Ye et al., 2015). Where
drug effects follow a ‘U-shaped’ response, the focal nature
of FTLD presents a special challenge. Take the behavioural
variant of FTD as an example. If prefrontal and temporal
cortex are deﬁcient in a given neurotransmitter (whether
neuronal density, receptor density, or afferent projections),
but motor, parietal and occipital cortex are not, then any
systemic treatment based on restoring that neurotransmitter
in frontal and temporal cortex will risk ‘overdosing’ the
unaffected areas. This problem is well established in
Parkinson’s disease, in the sometimes difﬁcult balance be-
tween motor disability and impulse control disorders
(Napier et al., 2015). The application of focal treatments
to restore biochemical function, such as dopaminergic stem
cell transplants or gene therapy to induce dopamine syn-
thesis in striatal cells, can overcome some of the adverse
consequences of systemic drug treatment in Parkinson’s dis-
ease. However, such localized treatments seem even more
challenging in a diffuse lobar cortical disorder. Similarly,
the use of Designer Receptors Exclusively Activated by
Designer Drugs (DREADDs) to restore or enhance focal
and selective neurotransmitter systems is having a major
impact in drug discovery and systems neuroscience (Roth,
2016), but seems far from direct clinical applications. For
the time being, systemic drug delivery is likely to be the
mainstay of clinical therapeutics.
We suggest three steps to improve the likelihood of new
and effective pharmacological treatments. First, clariﬁcation
of the links between individual neurotransmitters and spe-
ciﬁc clinical end-points. We suggest that identifying the
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neurotransmitter deﬁcits that correlate with clinical severity
is essential to guide treatment studies. This evidence may
draw on in vivo imaging and CSF studies and post-mortem
immunohistochemistry of cases that have been regularly
phenotyped during disease progression. This would be a
considerable undertaking, but possible if added to existing
longitudinal studies (Rohrer et al., 2015b; Woodside et al.,
2016).
Second, it is essential to implement stratiﬁcation of pa-
tients in future trials, selecting participants for their rele-
vant symptoms rather than the diagnosis alone. For
example, in a trial to demonstrate a clinical effect of ser-
otonergic treatment on impulsivity in bvFTD, based on ex-
perimental medicines evidence (Hughes et al., 2015),
participants should not merely have bvFTD by consensus
criteria, but also have impulsivity; noting that disinhibition
is one of six criteria whereas only three are required for the
diagnosis. Including patients with bvFTD who are not dis-
inhibited is likely to reduce the power of a symptomatic
treatment trial. Moreover, it may be better to include all
patients with disinhibition arising from syndromes asso-
ciated with FTLD in which disinhibition is common but
not a diagnostic criterion (including semantic variant
PPA, CBS and PSP) (Lansdall et al., 2017). This would
increase the power and relevance of the trial to a wider
patient group.
Third, future clinical trials need careful selection of rele-
vant outcome tools, especially where drugs are repurposed
for new end-points. For example, selective serotonin reup-
take inhibitors are licenced for affective disorders but it
would be wrong to use a depression rating scale in
bvFTD or PSP where the expected effect is on impulsivity.
Similarly, cholinesterase inhibitors are licenced for
Alzheimer’s disease for their effect on cognition but cogni-
tive function scales would be inappropriate if the intended
effect in say PSP were on gait and balance.
For each of the disorders associated with FTLD, it is
likely that experimental medicines studies with biomarker
based surrogate end-points are needed before randomized
placebo controlled clinical trials are started. The evidence
presented in this review suggests that there are strong
grounds to pursue such experimental medicine studies,
drawing on the preclinical psychopharmacology models
and patient data, to minimize the risks of clinical trials.
There are many candidate end-points, to demonstrate
human target engagement and efﬁcacy in the CNS. These
may be used singly or in combination, including functional
imaging; magnetic resonance spectroscopy (Cai et al., 2012;
Muthukumaraswamy et al., 2013); PET imaging of neuro-
transmitters receptors and occupancy; magneto-/electro-en-
cephalographic physiological indices of oscillatory
dynamics (Muthukumaraswamy, 2014), focal function
(Hughes et al., 2015) and network interactions (Moran
et al., 2011, 2013; Hughes et al., 2013; Gilbert et al.,
2016); CSF biomarkers; and neurocognitive batteries
(Kehagia et al., 2014).
This review has focused on the symptomatic beneﬁts of
restoring neurotransmitters. However, some of these
agents, like trazodone, have wider effects on pathogenesis
and neuronal survival that may also lead to disease modi-
ﬁcation or slowing of disease progression (Halliday et al.,
2017). Even where the principal effect is symptomatic, this
may improve survival, such as the impact of dopaminergic
therapy in Parkinson’s disease after its introduction in the
late 1960’s (Uitti et al., 1993). Relief of apathy, disinhib-
ition, falls, and dementia in syndromes associated with
FTLD might therefore improve survival as well as interim
quality of life.
Finally, we note that there has been recent concern re-
garding international pharma investment in disorders of the
CNS (Fineberg et al., 2013). However, we suggest that
there is scope and grounds for optimism for progress to-
wards effective symptomatic pharmacological therapies.
Such treatments, based on restoring neurotransmitter def-
icits, would reduce the cost, social and health burden of
FTLD.
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